Lanlan Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lanlan Wei has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
Siwei Zhang
Institute for Hepatology, Shenzhen Third People’s Hospital, The Second Hospital Affiliated to Southern University of Science and Technology
8 shared publicationsTianyang Liu
Institute for Hepatology, National Clinical Research Center for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen
8 shared publicationsShanshan Tang
People’s Hospital of Naxi District, Luzhou
5 shared publicationsYao Wang
Institute for Hepatology, National Clinical Research Center for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen
5 shared publicationsBingqing Yan
Nantong Center for Disease Control and Prevention, Nantong, Jiangsu 226007, PR China
4 shared publicationsFangjia Tong
National Clinical Research Center for Infectious Diseases, The Third People’s Hospital of Shenzhen, The Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, Guangdong, China
4 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1878265
Comparison of clinical characteristics in acute and early HIV-1 infection across different subtypes: a hospital-based cohort study
Background: Early diagnosis and immediate antiretroviral therapy (ART) for acute and early HIV-1 infection (AEHI) effectively curb HIV transmission and restrict viral reservoir formation. However, subtype-specific transmitted drug resistance (TDR) and early ART virological response remain insufficiently characterized among circulating HIV-1 recombinants in the Guangdong-Hong Kong-Macao Greater Bay Area. This study aimed to compare these key indicators across different HIV-1 subtypes. Methods: This hospital-based cohort study enrolled 105 AEHI patients from 2019 to 2024. HIV-1 pol gene sequencing was performed for subtype classification and drug resistance genotyping. Antiretroviral therapy responses were monitored at weeks 4, 12, 24, and 48. Demographic, clinical, virological, immunological, and TDR data were systematically analyzed across all HIV-1 subtypes. Results: CRF07_BC was the dominant strain (32.4%), followed by other BC recombinants (30.5%) and CRF01_AE (22.9%). Poppers use was significantly associated with CRF07_BC transmission among MSM ( P = 0.007). The B+CRF01_AE/CRF55_01B group exhibited an extremely high TDR rate of 90.9% ( P < 0.001), dominated by V179E and M184V mutations. At weeks 12 and 24 post-ART, BC recombinants and B+CRF01_AE/CRF55_01B showed slower viral suppression than CRF07_BC, while all subtypes achieved comparable long-term immune recovery (92.6% virological suppression at week 48). Conclusion: Significant heterogeneity in TDR and early viral load suppression exists among HIV-1 subtypes during acute infection. Baseline drug resistance testing and intensified viral load monitoring are recommended for patients with B/CRF01_AE recombinant strains. These findings support regional HIV molecular surveillance and subtype-targeted early intervention.
- 17 July 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1878265
Open AccessComparison of clinical characteristics in acute and early HIV-1 infection across different subtypes: a hospital-based cohort study
Background: Early diagnosis and immediate antiretroviral therapy (ART) for acute and early HIV-1 infection (AEHI) effectively curb HIV transmission and restrict viral reservoir formation. However, subtype-specific transmitted drug resistance (TDR) and early ART virological response remain insufficiently characterized among circulating HIV-1 recombinants in the Guangdong-Hong Kong-Macao Greater Bay Area. This study aimed to compare these key indicators across different HIV-1 subtypes. Methods: This hospital-based cohort study enrolled 105 AEHI patients from 2019 to 2024. HIV-1 pol gene sequencing was performed for subtype classification and drug resistance genotyping. Antiretroviral therapy responses were monitored at weeks 4, 12, 24, and 48. Demographic, clinical, virological, immunological, and TDR data were systematically analyzed across all HIV-1 subtypes. Results: CRF07_BC was the dominant strain (32.4%), followed by other BC recombinants (30.5%) and CRF01_AE (22.9%). Poppers use was significantly associated with CRF07_BC transmission among MSM ( P = 0.007). The B+CRF01_AE/CRF55_01B group exhibited an extremely high TDR rate of 90.9% ( P < 0.001), dominated by V179E and M184V mutations. At weeks 12 and 24 post-ART, BC recombinants and B+CRF01_AE/CRF55_01B showed slower viral suppression than CRF07_BC, while all subtypes achieved comparable long-term immune recovery (92.6% virological suppression at week 48). Conclusion: Significant heterogeneity in TDR and early viral load suppression exists among HIV-1 subtypes during acute infection. Baseline drug resistance testing and intensified viral load monitoring are recommended for patients with B/CRF01_AE recombinant strains. These findings support regional HIV molecular surveillance and subtype-targeted early intervention.
- Open Access
- 4 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1795238
Correction: HIV subtype-specific gp140-CD4 binding, Temsavir efficacy, and identification of novel adhesion inhibitors against Chinese HIV strains
Correction on: Liu T, Li X, Yang X, Zhang S, Wang Y, Zhang S, Cheng L, Tang S, Wang F, Zhao Y, Lu H and Wei L (2025) HIV subtype-specific gp140-CD4 binding, Temsavir efficacy, and identification of novel adhesion inhibitors against Chinese HIV strains. Front. Immunol. 16:1648546. doi: 10.3389/fimmu.2025.1648546 An incorrect number was provided for the Shenzhen Science and Technology Innovation Program. The correct number is "(KCXFZ20211020163544002)"The original version of this article has been updated.for a reason not seen here, please contact the journal's editorial office.
- 4 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1795238
Open AccessCorrection: HIV subtype-specific gp140-CD4 binding, Temsavir efficacy, and identification of novel adhesion inhibitors against Chinese HIV strains
Correction on: Liu T, Li X, Yang X, Zhang S, Wang Y, Zhang S, Cheng L, Tang S, Wang F, Zhao Y, Lu H and Wei L (2025) HIV subtype-specific gp140-CD4 binding, Temsavir efficacy, and identification of novel adhesion inhibitors against Chinese HIV strains. Front. Immunol. 16:1648546. doi: 10.3389/fimmu.2025.1648546 An incorrect number was provided for the Shenzhen Science and Technology Innovation Program. The correct number is "(KCXFZ20211020163544002)"The original version of this article has been updated.for a reason not seen here, please contact the journal's editorial office.
- Open Access
- 1 January 2026
- Published by Tech Science Press in Oncology Research
- Vol. 34 (1) , 1-10
P2RX1 Influences the Prognosis of Ph+/Ph-Like ALL through Energy and Calcium Metabolism
Objectives: Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia and Philadelphia-like B-cell acute lymphoblastic leukemia (Ph+/Ph-like ALL) constitute the majority of relapsed/refractory B-ALL (R/R B-ALL) cases, highlighting an urgent need to discover new therapeutic targets. This study aims to elucidate the mechanisms underlying poor prognosis in Ph+/Ph-like ALL through transcriptome sequencing and functional cytological assays, with the goal of informing new clinical treatment strategies. Results: Transcriptomic analysis of Ph+/Ph-like ALL patients revealed that low expression of P2X Purinoceptor 1 (P2RX1) was associated with unfavorable outcomes. Specifically, patients with poor prognosis and low P2RX1 expression exhibited downregulation of genes involved in energy and calcium metabolism pathways, along with upregulation of genes governing key cellular processes such as cell proliferation (e.g., MYC), cell cycle progression (e.g., CCND2), and apoptosis inhibition (e.g., DASP6). Cellular experiments demonstrated that SUP-B15 cells overexpressing P2RX1 displayed elevated intracellular levels of ATP, calcium, and glucose, together with enhanced glycolytic capacity, compared to empty vector controls. Treatment of SUP-B15 cells with dexamethasone (Dex), Imatinib, or their combination significantly suppressed proliferation and promoted apoptosis, which was accompanied by increases in intracellular ATP, calcium, and glucose. Moreover, exogenous ATP administration (a P2RX1 agonist) enhanced apoptosis and inhibited proliferation in control cells. Conversely, treatment with NF449 (a P2RX1 inhibitor) increased proliferation in both P2RX1-overexpressing and control SUP-B15 cells. Conclusion: Our findings indicate that P2RX1 may exert this function through modulating energy metabolism and calcium homeostasis, resulting in elevated intracellular calcium levels. Sustained elevation of calcium promotes apoptosis, whereas exogenous ATP activates P2RX1, enhances calcium influx, and attenuates the suppression of apoptosis associated with P2RX1 underexpression, ultimately correlating with improved treatment response.
- 1 January 2026
- Published by Tech Science Press in Oncology Research
- Vol. 34 (1) , 1-10
Open AccessP2RX1 Influences the Prognosis of Ph+/Ph-Like ALL through Energy and Calcium Metabolism
Objectives: Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia and Philadelphia-like B-cell acute lymphoblastic leukemia (Ph+/Ph-like ALL) constitute the majority of relapsed/refractory B-ALL (R/R B-ALL) cases, highlighting an urgent need to discover new therapeutic targets. This study aims to elucidate the mechanisms underlying poor prognosis in Ph+/Ph-like ALL through transcriptome sequencing and functional cytological assays, with the goal of informing new clinical treatment strategies. Results: Transcriptomic analysis of Ph+/Ph-like ALL patients revealed that low expression of P2X Purinoceptor 1 (P2RX1) was associated with unfavorable outcomes. Specifically, patients with poor prognosis and low P2RX1 expression exhibited downregulation of genes involved in energy and calcium metabolism pathways, along with upregulation of genes governing key cellular processes such as cell proliferation (e.g., MYC), cell cycle progression (e.g., CCND2), and apoptosis inhibition (e.g., DASP6). Cellular experiments demonstrated that SUP-B15 cells overexpressing P2RX1 displayed elevated intracellular levels of ATP, calcium, and glucose, together with enhanced glycolytic capacity, compared to empty vector controls. Treatment of SUP-B15 cells with dexamethasone (Dex), Imatinib, or their combination significantly suppressed proliferation and promoted apoptosis, which was accompanied by increases in intracellular ATP, calcium, and glucose. Moreover, exogenous ATP administration (a P2RX1 agonist) enhanced apoptosis and inhibited proliferation in control cells. Conversely, treatment with NF449 (a P2RX1 inhibitor) increased proliferation in both P2RX1-overexpressing and control SUP-B15 cells. Conclusion: Our findings indicate that P2RX1 may exert this function through modulating energy metabolism and calcium homeostasis, resulting in elevated intracellular calcium levels. Sustained elevation of calcium promotes apoptosis, whereas exogenous ATP activates P2RX1, enhances calcium influx, and attenuates the suppression of apoptosis associated with P2RX1 underexpression, ultimately correlating with improved treatment response.
- Open Access
- 27 November 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1693487
M1 macrophage-derived exosomal miR-20b promotes radiosensitization via CCND1 in HPV+ HNSCC
Background: Human papillomavirus (HPV) is a significant risk factor for head and neck squamous cell carcinoma (HNSCC). HPV positive (HPV + ) HNSCC is more sensitive to radiotherapy and has a better prognosis than HPV negative (HPV - ) HNSCC. M1 macrophages not only enhance the radiosensitivity of HPV+ HNSCC, but the M1 macrophages derived exosmoes (M1 exos) also possess anti-tumor activity. However, the role of M1 exos in the radiosensitivity of HNSCC remains unclear. Materials and methods: HPV status and macrophage infiltration levels in 25 HNSCC tissues were evaluated by immunohistochemistry (IHC). M1 macrophages were induced and cultured in vitro , and exosomes were extracted through differential ultracentrifugation. The effect of M1 exos on the radiosensitivity of HPV + HNSCC was assessed via an in vitro co-culture system. The expression level of γ-H2AX was assessed by immunofluorescence. The levels of miR-20b in HNSCC were analyzed using multicenter data (from TCGA and GEO databases), along with their correlation to radiosensitivity and prognosis. Cellular experiments demonstrated that overexpressing miR-20b significantly enhanced radiosensitivity in HPV+ HNSCC. Bioinformatic and experimental validation identified CCND1 as a target of miR-20b. Results: In HPV + HNSCC, M1 macrophages were highly infiltrated and played a crucial role in improving the therapeutic effect of HPV + HNSCC. M1 exos infiltrated HPV + HNSCC, increasing their sensitivity to radiation. Meanwhile, M1 macrophages exhibited higher miR-20b levels than M2 macrophages, and the radiosensitivity of HPV + HNSCC was significantly increased by transfecting them with a miR-20b mimic. Functional analysis of target genes, CCND1 as a key gene through which miR-20b enhanced radiosensitivity in HPV + HNSCC. Conclusion: In this study, our results suggest that M1 exos, enriched with miR-20b, regulate the DNA damage repair pathway in tumor cells by targeting CCND1, enhancing the radiosensitivity of HPV + HNSCC.
- 27 November 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1693487
Open AccessM1 macrophage-derived exosomal miR-20b promotes radiosensitization via CCND1 in HPV+ HNSCC
Background: Human papillomavirus (HPV) is a significant risk factor for head and neck squamous cell carcinoma (HNSCC). HPV positive (HPV + ) HNSCC is more sensitive to radiotherapy and has a better prognosis than HPV negative (HPV - ) HNSCC. M1 macrophages not only enhance the radiosensitivity of HPV+ HNSCC, but the M1 macrophages derived exosmoes (M1 exos) also possess anti-tumor activity. However, the role of M1 exos in the radiosensitivity of HNSCC remains unclear. Materials and methods: HPV status and macrophage infiltration levels in 25 HNSCC tissues were evaluated by immunohistochemistry (IHC). M1 macrophages were induced and cultured in vitro , and exosomes were extracted through differential ultracentrifugation. The effect of M1 exos on the radiosensitivity of HPV + HNSCC was assessed via an in vitro co-culture system. The expression level of γ-H2AX was assessed by immunofluorescence. The levels of miR-20b in HNSCC were analyzed using multicenter data (from TCGA and GEO databases), along with their correlation to radiosensitivity and prognosis. Cellular experiments demonstrated that overexpressing miR-20b significantly enhanced radiosensitivity in HPV+ HNSCC. Bioinformatic and experimental validation identified CCND1 as a target of miR-20b. Results: In HPV + HNSCC, M1 macrophages were highly infiltrated and played a crucial role in improving the therapeutic effect of HPV + HNSCC. M1 exos infiltrated HPV + HNSCC, increasing their sensitivity to radiation. Meanwhile, M1 macrophages exhibited higher miR-20b levels than M2 macrophages, and the radiosensitivity of HPV + HNSCC was significantly increased by transfecting them with a miR-20b mimic. Functional analysis of target genes, CCND1 as a key gene through which miR-20b enhanced radiosensitivity in HPV + HNSCC. Conclusion: In this study, our results suggest that M1 exos, enriched with miR-20b, regulate the DNA damage repair pathway in tumor cells by targeting CCND1, enhancing the radiosensitivity of HPV + HNSCC.
- Open Access
- 5 November 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1690348
Incidence and persistent infection rates of type-specific HPV among HIV-infected males in China: a 5-year retrospective study
Background: Although the 9-valent HPV vaccine (9v-HPV) has been approved for males in China, it has received limited public attention. This study aimed to explore the incidence and persistence of different HPV types in HIV-related males and emphasize the importance of vaccination. Methods: A cohort of 758 male patients with multiple HPV detection (≥3) from 2018 to 2023 in our hospital were enrolled for statistical analysis, including 113 Men who have Sex with Men (MSM) patients. HIV and HPV infection statuses were confirmed respectively by ELISA, PCR, WB and nucleic acid kit. Results: Statistical analysis revealed that the incidence of 9v-HPV-covered high-risk (HR) HPV infections were 68.1% (HIV + total males), 43.2% (HIV − total males), 67.6% (HIV + MSM) and 42.2% (HIV − MSM). HPV persistence was significantly prolonged in HIV + patients than HIV − cases ( p < 0.001). Markov model demonstrated that HIV increased incidence risks of HPV52, 58, 45, 35, 39, 51, 59, 68, 66, 73, 82, 81 and reduced the clearance rates of HPV16, 18, 6, 11, 58, 33, 31, 56 in males. Discussion: These findings highlight the increased burden of HPV infection among HIV + individuals. Timely vaccination will benefit males by preventing HPV infection and consequently reducing the associated disease burden.
- 5 November 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1690348
Open AccessIncidence and persistent infection rates of type-specific HPV among HIV-infected males in China: a 5-year retrospective study
Background: Although the 9-valent HPV vaccine (9v-HPV) has been approved for males in China, it has received limited public attention. This study aimed to explore the incidence and persistence of different HPV types in HIV-related males and emphasize the importance of vaccination. Methods: A cohort of 758 male patients with multiple HPV detection (≥3) from 2018 to 2023 in our hospital were enrolled for statistical analysis, including 113 Men who have Sex with Men (MSM) patients. HIV and HPV infection statuses were confirmed respectively by ELISA, PCR, WB and nucleic acid kit. Results: Statistical analysis revealed that the incidence of 9v-HPV-covered high-risk (HR) HPV infections were 68.1% (HIV + total males), 43.2% (HIV − total males), 67.6% (HIV + MSM) and 42.2% (HIV − MSM). HPV persistence was significantly prolonged in HIV + patients than HIV − cases ( p < 0.001). Markov model demonstrated that HIV increased incidence risks of HPV52, 58, 45, 35, 39, 51, 59, 68, 66, 73, 82, 81 and reduced the clearance rates of HPV16, 18, 6, 11, 58, 33, 31, 56 in males. Discussion: These findings highlight the increased burden of HPV infection among HIV + individuals. Timely vaccination will benefit males by preventing HPV infection and consequently reducing the associated disease burden.
- Open Access
- 22 September 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1648546
HIV subtype-specific gp140-CD4 binding, Temsavir efficacy, and identification of novel adhesion inhibitors against Chinese HIV strains
Introduction: The HIV epidemic in China is characterized by significant genetic diversity with multiple circulating recombinant forms (CRFs). The gp120-CD4 interaction, essential for viral cellular entry, exhibits subtype-dependent structural variations that compromise therapeutic efficacy. Although temsavir remains the only FDA-approved adhesion inhibitor, its activity against predominant HIV subtypes in China has not been systematically evaluated. Methods: HIV subtyping of 472 clinical samples identified five major strains (B, CRF01_AE, CRF07_BC, CRF08_BC, and CRF55_01B). Recombinant gp140 proteins from these subtypes were expressed, purified, and analyzed via bio-layer interferometry (BLI) to characterize CD4 binding properties. Structural analyses compared hydrogen bonding and interface buried surface areas. Temsavir’s inhibitory efficacy was assessed, and virtual screening of 13,819 compounds combined with BLI validation was performed to identify novel inhibitors. Results: Subtype B demonstrated the strongest CD4 binding affinity (KD=79 pM), while CRF55_01B showed the weakest binding (KD=8.76 nM). CRF variants exhibited reduced hydrogen bonding and smaller interface buried surface areas, correlating with diminished binding affinity. Temsavir inhibition was subtype-dependent, achieving 35.7% inhibition for subtype B versus <1.3% for CRF01_AE and CRF55_01B, primarily due to steric hindrance induced by the S375H mutation. Five novel inhibitors targeting CRF55_01B were identified with inhibition rates 19%. Discussion: This study elucidates the molecular mechanisms of HIV-1 adhesion variation and provides specific candidate HIV adhesion inhibitors for prevalent CRF subtypes in China. Subsequent efforts will focus on preclinical validation and structure–activity relationship optimization of these candidates, laying the groundwork for developing personalized therapeutic strategies against region-specific strains.
- 22 September 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1648546
Open AccessHIV subtype-specific gp140-CD4 binding, Temsavir efficacy, and identification of novel adhesion inhibitors against Chinese HIV strains
Introduction: The HIV epidemic in China is characterized by significant genetic diversity with multiple circulating recombinant forms (CRFs). The gp120-CD4 interaction, essential for viral cellular entry, exhibits subtype-dependent structural variations that compromise therapeutic efficacy. Although temsavir remains the only FDA-approved adhesion inhibitor, its activity against predominant HIV subtypes in China has not been systematically evaluated. Methods: HIV subtyping of 472 clinical samples identified five major strains (B, CRF01_AE, CRF07_BC, CRF08_BC, and CRF55_01B). Recombinant gp140 proteins from these subtypes were expressed, purified, and analyzed via bio-layer interferometry (BLI) to characterize CD4 binding properties. Structural analyses compared hydrogen bonding and interface buried surface areas. Temsavir’s inhibitory efficacy was assessed, and virtual screening of 13,819 compounds combined with BLI validation was performed to identify novel inhibitors. Results: Subtype B demonstrated the strongest CD4 binding affinity (KD=79 pM), while CRF55_01B showed the weakest binding (KD=8.76 nM). CRF variants exhibited reduced hydrogen bonding and smaller interface buried surface areas, correlating with diminished binding affinity. Temsavir inhibition was subtype-dependent, achieving 35.7% inhibition for subtype B versus <1.3% for CRF01_AE and CRF55_01B, primarily due to steric hindrance induced by the S375H mutation. Five novel inhibitors targeting CRF55_01B were identified with inhibition rates 19%. Discussion: This study elucidates the molecular mechanisms of HIV-1 adhesion variation and provides specific candidate HIV adhesion inhibitors for prevalent CRF subtypes in China. Subsequent efforts will focus on preclinical validation and structure–activity relationship optimization of these candidates, laying the groundwork for developing personalized therapeutic strategies against region-specific strains.
- 3 June 2025
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 113 (3) , 116932
Clinical indicators associated with tuberculous meningitis using multiple correspondence analysis
- 3 June 2025
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 113 (3) , 116932
Clinical indicators associated with tuberculous meningitis using multiple correspondence analysis
- Open Access
- 28 May 2025
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 18 (9) , 102845
RPA-CRISPR/Cas12a detection based on HCMV-UL123 gene: A way with higher detection rate than clinical detection methods
- 28 May 2025
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 18 (9) , 102845
Open AccessRPA-CRISPR/Cas12a detection based on HCMV-UL123 gene: A way with higher detection rate than clinical detection methods
- Open Access
- 6 November 2024
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 17 (12) , 102586
Epidemiological and typing features of HPV co-infections in MSM with mpox: A hospital-based prospective study
- 6 November 2024
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 17 (12) , 102586
Open AccessEpidemiological and typing features of HPV co-infections in MSM with mpox: A hospital-based prospective study
- 28 March 2023
- Published by Elsevier in Oral Oncology
- Vol. 140, 106367
Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma
- 28 March 2023
- Published by Elsevier in Oral Oncology
- Vol. 140, 106367
Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma